Merck faces critical Keytruda patent cliff
Merck's intense dependency on blockbuster Keytruda creates significant revenue risk ahead of its 2028 patent expiration.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.